在以前的工作中 ,我们利用本研究室制备的抗胶质瘤单克隆抗体ＳＺ39通过化学偶联的方法制备了抗ＣＤ3/抗胶质瘤双特异性抗体 ,并在体外细胞毒及荷瘤动物体内试验中取得较好疗效[1,2 ] ,但存在着分子量大 ,穿透力弱 ,免疫原性强 ,制备困难等缺点。因此 ,研制小分子 ,低免疫原性 In our previous work, we used an anti-glioma monoclonal antibody SZ39 prepared in our lab to prepare anti-CD3 / anti-glioma bispecific antibodies by chemical conjugation, and in vitro cytotoxic and tumor-bearing animals In vivo tests to obtain better efficacy [1,2], but there is a large molecular weight, weak penetration, strong immunogenicity, preparation and other shortcomings. Therefore, the development of small molecules, low immunogenicity